Latest Hotspot

Testing Dosage of New T-cell Engager, ARB202, in Advanced Gastrointestinal Cancer Patients

30 April 2024
3 min read

Arbele, a biotechnology firm in the clinical phase that specializes in creating new immunotherapy treatments specifically for advanced gastrointestinal cancers, has received a favorable recommendation from the Data Monitoring Committee during its second meeting. The committee endorsed the continuation of the A001 Phase I clinical trial, which assesses the effectiveness of cabotamig (ARB202) in individuals battling advanced gastrointestinal cancers, without any changes to the study's protocol.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

This evaluation of safety was conducted through the analysis of data obtained from 18 individuals, including those who received several treatments with cabotamig. The favorable recommendation reaffirms that the tolerability of cabotamig aligns with the existing safety profiles for T-cell engagers used in different medical conditions.

"We owe a great deal of gratitude to the brave participants of this initial cabotamig study, which has enhanced our comprehension of its safety characteristics and helped refine the dosage for this hopeful treatment," stated Dr. Dennis Wong, the Chief Medical Officer at Arbele.

The A001 study is designed as a multi-center, open-label, First-in-Human (FIH) continuous trial. Its purpose is assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of cabotamig when delivered intravenously to patients with advanced GI malignancies unresponsive to conventional treatments and which express CDH17. The initial segment of this research includes a dose-escalation phase with about 28 participants, followed by a study where multiple doses are progressively increased or ranged.

Screening for tumors expressing CDH17 is mandatory for all participants except those with colorectal cancer, utilizing the TibTech automated diagnostic tissue platform. Patients exhibiting CDH17 will proceed to screening for dosage eligibility. Conversely, those with colorectal cancer do not require CDH17 marker tests for eligibility.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of April 30, 2024, there are 2 investigational drugs for the CD3 and CDH17 target, including 4 indications, 1 R&D institutions involved, and as many as 316 patents.

Cabotamig shows promise as a potential treatment for gastrointestinal neoplasms, biliary tract neoplasms, and pancreatic carcinoma. However, further research and clinical trials are needed to assess its efficacy and safety in larger patient populations. The Phase 1 trial will provide valuable insights into the drug's potential and pave the way for further development and testing in subsequent phases.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 29
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 29
29 April 2024
April 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
Latest Hotspot
3 min read
Cidara Therapeutics Retakes Global Rights to CD388, Initiates $240M Funding Drive
28 April 2024
Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.
Read →
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
Hot Spotlight
3 min read
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
28 April 2024
On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.
Read →
FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
Latest Hotspot
3 min read
FDA Prioritizes GSK's Proposal to Expand Jemperli Use with Chemotherapy in Advanced Endometrial Cancer
28 April 2024
FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.